Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 8/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15923708 | 0.84 | CHRM4 (0.35) | KDM4ECHRM4GRM4GRM2 | |
| SCHEMBL15935163 | 0.82 | MAPT (0.45) | MAPTRAB9AKDM4EALDH1A1GAA | |
| SCHEMBL15935205 | 0.82 | MAPT (0.45) | MAPTRAB9AKDM4EALDH1A1GAA | |
| SCHEMBL30630538 | 0.80 | CHRM4 (0.40) | CHRM4GRM4 | |
| SCHEMBL17253137 | 0.79 | GAA (0.42) | MAPTRAB9AKDM4EALDH1A1GAA | |
| SCHEMBL16574219 | 0.72 | HSD17B1 (0.44) | MAPTRAB9AKDM4EALDH1A1GAA | |
| SCHEMBL24375514 | 0.72 | MEN1 (0.44) | MAPTRAB9AKDM4EALDH1A1GAA | |
| SCHEMBL16201983 | 0.71 | RAB9A (0.53) | MAPTRAB9AKDM4EALDH1A1GAA | |
| SCHEMBL16202102 | 0.71 | MAPT (0.53) | MAPTRAB9AKDM4EALDH1A1GAA | |
| SCHEMBL16963699 | 0.71 | ALDH1A1 (0.49) | MAPTRAB9AKDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2934538-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2021-03-31 | — | — | EP | disclosed |
| US-9708308-B2 | Factor IXa inhibitors | MERCK SHARP DOHME CORP. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20150322056-A1 | Factor IXa Inhibitors | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-11-12 | — | — | US | disclosed |
| WO-2014120346-A1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322056-A1 | Factor IXa Inhibitors | F9, F12, F8 | MAPT 4751/4885RAB9A 556/4885KDM4E 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.